I think the point is the peptide is not yet a drug so it needs a lot more work but as RH emphasised very exciting where it's at.
In more near term though the fact it can significantly improve the activity of existing cancer drugs both antibodies and small molecules surely increases interest. If you are looking at the drugs in question & the big pharma - Cetuximab - Ab (Lily, Merck, Bristol Myers Squibb) & Docetaxel - SM (Sanofi).
I also liked the start of the interview highlighting how they can deliver companies existing drugs "MUCH" more efficiently than they can.
FWIW on the whole increased promo trip of late I have no idea why they are not releasing interviews like this that they have taken the time do as NPS announcements on the ASX so they are reaching the market they are trying to attract & get the message out to the target audience.
PYC Price at posting:
3.7¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)